230 reports of this reaction
2.3% of all NALOXONE HYDROCHLORIDE reports
#7 most reported adverse reaction
DYSPNOEA is the #7 most commonly reported adverse reaction for NALOXONE HYDROCHLORIDE, manufactured by Emergent Devices Inc.. There are 230 FDA adverse event reports linking NALOXONE HYDROCHLORIDE to DYSPNOEA. This represents approximately 2.3% of all 10,081 adverse event reports for this drug.
Patients taking NALOXONE HYDROCHLORIDE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for NALOXONE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for NALOXONE HYDROCHLORIDE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 230 FDA reports for NALOXONE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.3% of all adverse event reports for NALOXONE HYDROCHLORIDE, making it a notable side effect.
If you experience dyspnoea while taking NALOXONE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.